Revenue and Sales Performance - In Q4 2024, nearly 2,500 prescriptions of ZURZUVAE were shipped, representing a 21% increase from Q3 2024, with over 6,600 prescriptions shipped for the full year[4] - Collaboration revenue from ZURZUVAE was $11.4 million in Q4 2024 and $36.1 million for the full year, accounting for 50% of net revenues recorded by Biogen[4] - The company anticipates a significant topline revenue growth in 2025 due to commercialization investments, including joint sales force expansions and digital marketing campaigns[3] - The company reported a strong repeat prescription rate of about 60% among targeted healthcare providers after prescribing ZURZUVAE[4] - Total revenues for the year ended December 31, 2024, were $41,243 thousand, a decrease of 52% compared to $86,455 thousand in 2023[20] - Product revenue, net for the three months ended December 31, 2024, was $442 thousand, down 78% from $1,985 thousand in the same period of 2023[20] - Collaboration revenue from related parties increased significantly to $36,087 thousand for the year ended December 31, 2024, compared to $824 thousand in 2023[20] Financial Position and Cash Flow - Cash, cash equivalents, and marketable securities totaled $504 million as of December 31, 2024, with a cash runway expected to support operations until mid-2027[1] - Cash, cash equivalents, and marketable securities decreased to $504,418 thousand as of December 31, 2024, down from $753,184 thousand in 2023, representing a decline of approximately 33%[18] - Total stockholder's equity decreased to $465,089 thousand as of December 31, 2024, down from $799,530 thousand in 2023, reflecting a decline of about 42%[18] Expenses and Losses - Research and development expenses decreased to $37.0 million in Q4 2024 from $64.3 million in Q4 2023, reflecting cost-saving measures and pipeline prioritization[10] - Selling, general and administrative expenses were $54.0 million in Q4 2024, a slight decrease from $55.1 million in Q4 2023, due to reorganization cost savings[13] - Net loss for Q4 2024 was $95.8 million, compared to $32.7 million in Q4 2023, with a total net loss of $400.7 million for the full year[13] - Research and development expenses for the year ended December 31, 2024, were $225,895 thousand, a reduction of 37% from $356,235 thousand in 2023[20] - The net loss for the year ended December 31, 2024, was $400,666 thousand, compared to a net loss of $541,489 thousand in 2023, indicating an improvement of approximately 26%[20] - Operating costs and expenses for the year ended December 31, 2024, totaled $473,613 thousand, a decrease of 29% from $666,304 thousand in 2023[20] - The company reported a net loss per share of $6.59 for the year ended December 31, 2024, compared to $9.05 in 2023, showing a reduction in loss per share of approximately 27%[20] Future Outlook and Challenges - The company expects to provide updates on SAGE-319 and SAGE-324 in mid-2025, focusing on potential treatments for neurodevelopmental disorders and seizures[5][7] - The company anticipates potential challenges in achieving anticipated cost savings from its reorganization and pipeline prioritization efforts scheduled for October 2024[20] - More than 70% of ZURZUVAE patients received it as their first new treatment for postpartum depression (PPD)[9]

Wall Street expects a year-over-year decline in earnings on lower revenues when Sage Therapeutics, Inc. (SAGE) reports results for the quarter ended December 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 11, 2025, might help the stock move higher if these key numbers are b ...

Sage Therapeutics (SAGE) announced that its board of directors has rejected the unsolicited, non-binding proposal offer from drug giant Biogen (BIIB) to acquire the remaining shares of SAGE.Per Sage Therapeutics, the BIIB offer significantly undervalues the company and is not in the best interest of shareholders.SAGE’s board of directors has now started exploring strategic alternatives and evaluating other options to maximize its shareholders’ value.Shares of SAGE were up 4.8% on Jan. 27 following the news ...

Sage Therapeutics, Inc. (SAGE) shares soared 35.1% in the last trading session to close at $7.50. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 3.1% gain over the past four weeks.The stock rallied after the company announced that its partner Biogen had made an unsolicited, non-binding proposal offer to acquire SAGE shares that it does not already own for $7.22 per share. The offer price represented a premium of 30% on Sage Ther ...

Sage Therapeutics, Inc. (SAGE) closed the last trading session at $6.14, gaining 9.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $8.72 indicates a 42% upside potential.The average comprises 18 short-term price targets ranging from a low of $4 to a high of $17, with a standard deviation of $3.54. While the lowest estimate indicates a decline of 34.9% from the current price leve ...

Sage Therapeutics, Inc. (SAGE) shares rallied 12.2% in the last trading session to close at $5.61. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.1% gain over the past four weeks.The company recently announced a strategic reorganization wherein it decided to focus on the commercialization of its depression drug Zurzuvae (zuranolone), which is marketed in partnership with Biogen. Zurzuvae is the first and o ...

Sage Therapeutics’ (SAGE) phase II study evaluating its neuropsychiatric candidate, dalzanemdor (SAGE-718), for treating cognitive impairment (CI) associated with Huntington’s Disease (HD) failed to meet the primary endpoint.The double-blind, placebo-controlled DIMENSION study evaluated the effects of dalzanemdor in participants with CI associated with HD.Top-line data from the study showed that dalzanemdor failed to demonstrate a statistically significant difference from baseline compared to placebo on the ...

Sage Therapeutics, Inc. (SAGE) reported a loss of $1.53 per share for the third quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.52. The company had reported a loss of $2.81 per share (excluding the restructuring expenses) in the year-ago quarter. Revenues in the third quarter totaled $11.8 million, significantly up from $2.7 million reported in the year-ago period. The upside can be attributed to sales of new depression drug Zurzuvae (zuranolone), which is marketed in partnership wi ...

Sage Therapeutics, Inc. (NASDAQ:SAGE) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Katie Plante - Manager of Investor Relations Barry E. Greene - Chief Executive Officer Chris Benecchi - Chief Business Officer Laura Gault - Chief Medical Officer Kimi Iguchi - Chief Financial Officer Mike Quirk - Chief Scientific Officer Conference Call Participants Anupam Rama - J.P. Morgan Salveen Richter - Goldman Sachs Yasmeen Rahimi - Piper Sandler Jay Olson - Oppenheimer Ami Fadia - ...

Third Quarter 2024 Financial Results October 29, 2024 Safe Harbor Statement • The slides presented today and the accompanying oral presentations contain forward-looking statements, which may be identified by the use of words such as "may," "might," "will," "should," "can," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "opportunity","goal", "mission", "vision", "potential," "target", or "continue," and other similar expressions. • Forward-looking statements in this pre ...